search
Back to results

Left Atrial Appendage Occlusion Study III (LAAOS III)

Primary Purpose

Cardiac Surgery With Cardiopulmonary Bypass, Atrial Fibrillation

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Left Atrial Appendage Occlusion
Sponsored by
Population Health Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Cardiac Surgery With Cardiopulmonary Bypass focused on measuring cardiac surgery, left atrial appendage, atrial fibrillation, stroke, non-CNS systemic embolism

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Greater than 18 years of age
  2. Undergoing a clinically indicated cardiac surgical procedure with the use of cardiopulmonary bypass
  3. Have a documented history of atrial fibrillation or atrial flutter
  4. CHA2DS2-VASc score ≥ 2
  5. Have provided informed consent

Exclusion Criteria:

  1. Patients undergoing off-pump cardiac surgery
  2. Patients undergoing any of the following procedures:

    • heart transplant
    • complex congenital heart surgery
    • sole indication for surgery is ventricular assist device insertion
    • previous cardiac surgery requiring opening of the pericardium
    • mechanical valve implant
  3. Patients who have had a previous placement of a percutaneous left atrial appendage closure device

Sites / Locations

  • Hamilton General Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Left Atrial Appendage Occlusion Group

No Left Atrial Appendage Occlusion Group

Arm Description

Surgeon will close the left atrial appendage using a suture and/or a surgical stapler or a regulatory approved atrial appendage closure device during the patient's cardiac surgery procedure.

Surgeon will not close the left atrial appendage during the patient's cardiac surgery procedure. Patient will be treated as per best medical practice for stroke prevention in atrial fibrillation. Treatment will be decided by the patient's primary care physician.

Outcomes

Primary Outcome Measures

Stroke or systemic arterial embolism
First occurrence of ischemic stroke or transient ischemic attack with positive neuroimaging or systemic arterial embolism

Secondary Outcome Measures

All cause stroke or transient ischemic attack with positive neuroimaging or systemic arterial embolism
All cause stroke or transient ischemic attack with positive neuroimaging or systemic arterial embolism
Ischemic stroke or transient ischemic attack with positive neuroimaging or systemic arterial embolism or death
Ischemic stroke* or transient ischemic attack with positive neuroimaging or systemic arterial embolism or death
Ischemic stroke or transient ischemic attack with positive neuroimaging or systemic arterial embolism > 30 days after surgery
Ischemic stroke or transient ischemic attack with positive neuroimaging or systemic arterial embolism > 30 days after surgery
Total mortality
Total mortality

Full Information

First Posted
March 20, 2012
Last Updated
January 12, 2022
Sponsor
Population Health Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT01561651
Brief Title
Left Atrial Appendage Occlusion Study III
Acronym
LAAOS III
Official Title
Left Atrial Appendage Occlusion Study III
Study Type
Interventional

2. Study Status

Record Verification Date
January 2022
Overall Recruitment Status
Completed
Study Start Date
July 2012 (Actual)
Primary Completion Date
April 2021 (Actual)
Study Completion Date
May 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Population Health Research Institute

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Atrial fibrillation (AF) is a common heart rhythm disorder that leads to one-sixth of all strokes. Prevention of strokes in AF is achieved through the use of blood thinners such as coumadin. Although these blood thinners are effective, they are limited by the risk of serious bleeding, by physician and patient reluctance to use, and by noncompliance and discontinuation. The left atrial appendage is a structure on the upper chamber of the heart that is the most common source of stroke in patients with AF. This structure is easily accessible during open heart surgery for removal, and has been an area of interest for stroke prevention. However, there is currently no strong evidence that removing it works. The LAAOS III trial will randomly (like the flip of a coin) assign patients with AF undergoing heart surgery for other reasons to have the left atrial appendage removed or not. These patients, other than this small procedure which has been shown to be quite safe, will be treated in the usual manner. The full study of 4700 patients, followed for an average of 4 years, will determine if removing the left atrial appendage can reduce stroke and other complications on top of usual therapy. A positive study will change the way heart surgery is performed on AF patients and results in a large reduction in the number of strokes in a large population. Further, it will promote further research into this approach that could be applied beyond AF patients undergoing heart surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiac Surgery With Cardiopulmonary Bypass, Atrial Fibrillation
Keywords
cardiac surgery, left atrial appendage, atrial fibrillation, stroke, non-CNS systemic embolism

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
4812 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Left Atrial Appendage Occlusion Group
Arm Type
Experimental
Arm Description
Surgeon will close the left atrial appendage using a suture and/or a surgical stapler or a regulatory approved atrial appendage closure device during the patient's cardiac surgery procedure.
Arm Title
No Left Atrial Appendage Occlusion Group
Arm Type
No Intervention
Arm Description
Surgeon will not close the left atrial appendage during the patient's cardiac surgery procedure. Patient will be treated as per best medical practice for stroke prevention in atrial fibrillation. Treatment will be decided by the patient's primary care physician.
Intervention Type
Other
Intervention Name(s)
Left Atrial Appendage Occlusion
Intervention Description
Surgeon will occlude the left atrial appendage using a suture and/or a surgical stapler or a regulatory approved atrial appendage closure during the patient's cardiac surgery procedure.
Primary Outcome Measure Information:
Title
Stroke or systemic arterial embolism
Description
First occurrence of ischemic stroke or transient ischemic attack with positive neuroimaging or systemic arterial embolism
Time Frame
Common termination point (median follow-up of 4 years)
Secondary Outcome Measure Information:
Title
All cause stroke or transient ischemic attack with positive neuroimaging or systemic arterial embolism
Description
All cause stroke or transient ischemic attack with positive neuroimaging or systemic arterial embolism
Time Frame
Common termination point (median follow-up of 4 years)
Title
Ischemic stroke or transient ischemic attack with positive neuroimaging or systemic arterial embolism or death
Description
Ischemic stroke* or transient ischemic attack with positive neuroimaging or systemic arterial embolism or death
Time Frame
Common termination point (median follow-up of 4 years)
Title
Ischemic stroke or transient ischemic attack with positive neuroimaging or systemic arterial embolism > 30 days after surgery
Description
Ischemic stroke or transient ischemic attack with positive neuroimaging or systemic arterial embolism > 30 days after surgery
Time Frame
Common termination point (median follow-up of 4 years)
Title
Total mortality
Description
Total mortality
Time Frame
Common termination point (median follow-up of 4 years)
Other Pre-specified Outcome Measures:
Title
Readmission for heart failure
Description
Readmission for heart failure
Time Frame
Common termination point (median follow-up of 4 years)
Title
Post-operative safety outcomes
Description
Operative safety outcomes (30-day mortality, chest tube output in the first post-operative 24 hours, rate of post-operative re-exploration for bleeding)
Time Frame
30 days post-surgery
Title
Major bleeding
Description
Major bleeding
Time Frame
Common termination point (median follow-up of 4 years)
Title
Myocardial infarction
Description
Myocardial infarction
Time Frame
Common termination point (median follow-up of 4 years)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Greater than 18 years of age Undergoing a clinically indicated cardiac surgical procedure with the use of cardiopulmonary bypass Have a documented history of atrial fibrillation or atrial flutter CHA2DS2-VASc score ≥ 2 Have provided informed consent Exclusion Criteria: Patients undergoing off-pump cardiac surgery Patients undergoing any of the following procedures: heart transplant complex congenital heart surgery sole indication for surgery is ventricular assist device insertion previous cardiac surgery requiring opening of the pericardium mechanical valve implant Patients who have had a previous placement of a percutaneous left atrial appendage closure device
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Richard Whitlock, MD
Organizational Affiliation
Population Health Research Institute/McMaster University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Stuart Connolly, MD, PhD
Organizational Affiliation
Population Health Research Institute/McMaster University
Official's Role
Study Chair
Facility Information:
Facility Name
Hamilton General Hospital
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8L 2X2
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
33999547
Citation
Whitlock RP, Belley-Cote EP, Paparella D, Healey JS, Brady K, Sharma M, Reents W, Budera P, Baddour AJ, Fila P, Devereaux PJ, Bogachev-Prokophiev A, Boening A, Teoh KHT, Tagarakis GI, Slaughter MS, Royse AG, McGuinness S, Alings M, Punjabi PP, Mazer CD, Folkeringa RJ, Colli A, Avezum A, Nakamya J, Balasubramanian K, Vincent J, Voisine P, Lamy A, Yusuf S, Connolly SJ; LAAOS III Investigators. Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke. N Engl J Med. 2021 Jun 3;384(22):2081-2091. doi: 10.1056/NEJMoa2101897. Epub 2021 May 15.
Results Reference
derived

Learn more about this trial

Left Atrial Appendage Occlusion Study III

We'll reach out to this number within 24 hrs